SPR113 shows excellent anti-mycobacterial activity in an in vitro system of Mtb infected human macrophages with EC50 of < 50nM against MDR- and XDR-TB strains. SPR113 also shows a dose dependent in vivo efficacy in an MDR-TB infected murine model. The compound has very good oral and IV exposure in mice, shows stability in liver microsomes, is very selective with no CYP or hERG activity.
Compound